Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
When looking only at the original endpoint of metastasis-free survival by conventional imaging, the PROTEUS trial was not positive. This result is consistent with the negative ENZERAD trial, which tested a similar drug combination with radiation instead of surgery. This cross-trial consistency suggests adding an ARPI may not provide a substantial benefit in this setting.
Related Insights
Unlike in breast or bladder cancer, the significant improvement in pathologic response in the PROTEUS trial did not translate to a similarly impressive benefit in metastasis-free survival. This disconnect suggests that eliminating tumor in the prostate specimen is not a reliable surrogate for long-term outcomes in this disease setting.
When PSMA PET became the standard of care for detecting prostate cancer metastasis, the PROTEUS trial amended its protocol to include it alongside conventional imaging. The trial's positive Metastasis-Free Survival (MFS) result was driven by this composite endpoint, as the analysis using conventional imaging alone was not statistically significant.
PROTEUS changed its primary endpoint mid-study to include PSMA PET-detected metastasis. While this led to a statistically positive result, it raises concerns that the benefit is merely earlier detection (lead-time bias) rather than a true improvement in curing micrometastatic disease and improving overall survival.
Multiple trials, including PACIFIC-2, have shown no survival benefit from adding immunotherapy concurrently with chemoradiation for unresectable Stage III NSCLC. This suggests that concurrent radiation may disrupt the immune-activating pathways necessary for immunotherapy to work, a critical lesson for future trial designs.
Contrary to common belief, centralized radiology review isn't always superior. In blinded trials, local radiologists with specialist knowledge and clinical context can be as, or more, accurate. The PROTEUS trial's investigator-assessed Metastasis-Free Survival (MFS) showed an even stronger treatment effect (HR 0.74) than the blinded central review (HR 0.80).
Pivotal trials for PARP inhibitor and ARPI combinations (e.g., PROPEL, MAGNITUDE) enrolled patients who were largely ARPI-naive. However, in modern practice, most patients receive an ARPI earlier in their treatment. This creates significant uncertainty about the benefit of these combinations for the majority of today's patients.
The PROTEUS trial used two pathologic endpoints. The investigator suggests Residual Cancer Burden (RCB), which measures cellularity, is a more meaningful reflection of response than just residual tumor size. The RCB endpoint showed a much larger treatment effect (30% vs. 11%) compared to the tumor size endpoint (9% vs. 1%).
Despite meeting its primary endpoint, the PROTEUS trial provides no validated biomarkers to identify which patients actually benefit from the intensified therapy. This lack of a predictive signature means applying the results in the clinic amounts to uniform escalation, likely overtreating many patients for an uncertain benefit, making it difficult to implement.
The introduction of highly sensitive PSMA PET scans means established endpoints like Metastasis-Free Survival (MFS) may no longer be valid. A metastasis detected by PET likely has a different, better prognosis than one found with older imaging, requiring new validation for this key endpoint.
Event-free survival rates at four years were concerningly low in both arms of the PROTEUS trial. This suggests the trial may have enrolled a population with a very high baseline risk of recurrence, potentially including patients with pre-existing micrometastatic disease, which could limit the study's applicability to a broader high-risk population.